ClinicalTrials.gg
CompletedNCT03479892Updated Jun 26, 2019

A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity

A Phase 1 interventional study of NNC0194-0499 and Placebo in Metabolism and Nutrition Disorder and Obesity, sponsored by Novo Nordisk A/S. Completed at 1 site in United States. Open to participants aged 22 Years to 55 Years. Per ClinicalTrials.gov, last updated 2019-06-26.

Primary conditionObesityRegistry: Nutrition DisordersReclassifiedWhy we changed it
Registry
Nutrition Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Nutrition Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2019, 7 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
22 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 207 studies in Obesity by Novo Nordisk A/S — 48 open to participants now, 66 under way, 26 of them phase 3. Obesity · Novo Nordisk A/S.

Enrollment
128th of 166
57 · median 138
Started
2018
with 13 others
Phase 1
85 of 207
22 open now
Registered
35th of 207
by date

Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 128th largest by enrollment of the 166 interventional ones that give a count, is one of 14 that started in 2018, is one of 85 in phase 1, and was the 35th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

48 of the 207 studies in Obesity by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

43 more — sign in →

By country, each count listing its studies:

All 48 open studies →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 22 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 207 studies in Obesity by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study looks at a new study medicine for weight control in people with overweight or obesity. The aim of this study is to see if the study medicine is safe for people to take. The study also looks at how fast the body removes the study medicine. The participants will either get NNC0194-0499 (the study medicine) or placebo (a formula that looks like the medicine but does not have active ingredients). Which treatment the participants get is decided by chance. The participants will get 1 or more injections into the skin of stomach area once each week for 12 weeks. The study will last for about 4 to 5 months. The participants will have 18 visits to the clinic.

03

Conditions studied

  • Metabolism and Nutrition Disorder
  • Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

This study's enrollment of 57 is below the median of 67 across 9,016 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Nutrition Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
22 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male aged 22-55 years (both inclusive) or female aged 22-45 years (both inclusive) at the time of signing
  • Female must have regular menstrual cycle(defined as 24-35 days between 1st day of menses for two most recent menstrual periods, self-reported)
  • Female must have bilateral tubal ligation or must be willing to use non-hormonal intrauterine device or diaphragm /cervical cap with spermicide in combination with condom for male partner(s)
  • (BMI) between 27.0 and 39.9 kg/sqm (both inclusive). Overweight should be due to excess adipose tissue, as judged by the investigator
  • Considered by the investigator to be generally healthy based on the medical history, physical examination, and the results of vital signs, , and clinical laboratory tests performed during the screening visit

Exclusion criteria

Exclusion Criteria:

  • Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol
  • Use of prescription or non-prescription medicinal products including herbal products and non-routine vitamins, within 2 weeks prior to screening. Mild painkillers are allowed until 24 hours prior to screening
  • History or presence of bone disease or otherwise increased risk of bone fracture as evaluated by dual-energy x-ray absorptiometry and as judged by the investigator
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    NNC0194-0499

    Participants will receive increasing doses of NNC0194-0499. The treatment period from first treatment (Day 1) to end of the treatment (Day 85) will be 12 weeks.

    Drug: NNC0194-0499

  • Placebo comparator
    Placebo

    Participants will receive NNC0194-0499 matched placebo. The treatment period from first treatment (Day 1) to end of the treatment (Day 85) will be 12 weeks.

    Drug: Placebo

Interventions

  • Participants will receive NNC0194-0499 (s.c., in a lifted fold of the abdominal skin) injection once weekly at increasing doses of 3.0 mg, 9.0 mg, 27 mg, 60 mg, or 120 mg. Each participant will only be given one dose level. Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group.

  • DrugPlacebo

    Participants will receive once weekly injections of NNC0194-0499 matched placebo.

07

What researchers measure

Primary outcomes

  1. Number of treatment emergent adverse events (TEAEs)

    count of events

    Time frame: From first administration of NNC0194-0499 (Day 1) to follow-up (Day 112)

Secondary outcomes

  1. Change in heart rate

    measured in beats per minute

    Time frame: Baseline (Day 1), Follow-up (Day 112)

  2. Change in biochemistry

    Parameters: Calcium (total), Chloride, Magnesium, Phosphate (inorganic), Potassium, Sodium, Urea (blood urea nitrogen, BUN), Uric acid, Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Amylase, Aspartate aminotransferase (AST), Creatinine kinase (CK, total), Gamma glutamyltransferase (GGT), Lactase dehydrogenase, Lipase, Albumin, Bicarbonate, Bilirubin (total), Creatinine, High sensitivity C-reactive protein (hsCRP) and Total protein in SI units

    Time frame: Baseline (Day -1), Follow-up (Day 112)

  3. Change in haematology

    Parameters: Erythrocytes, Reticulocytes, Thrombocytes, Leucocytes (total), Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, Haemoglobin, Haematocrit, Mean corpuscular volume (MCV) and Mean corpuscular haemoglobin concentration (MCHC) in SI units

    Time frame: Baseline (Day -1), Follow-up (Day 112)

  4. Change in fibrinogen

    measured in g/L

    Time frame: Baseline (Day -1), Follow-up (Day 112)

  5. Change in prothrombin time read as international normalised ratio (INR)

    Time frame: Baseline (Day -1), Follow-up (Day 112)

  6. Change in activated partial thromboplastin time (APTT)

    measured in seconds

    Time frame: Baseline (Day -1), Follow-up (Day 112)

  7. Changes in electrocardiogram (ECG)

    Parameters: RR interval, PR interval, QRS interval, QT interval and QTcF interval in SI units

    Time frame: Baseline (Day 1), Follow-up (Day 112)

  8. Number of injection site reactions

    count of injection site reactions

    Time frame: From baseline (Day 1) to follow-up (Day 112)

  9. Occurrence of anti-NNC0194-0499 antibodies

    Time frame: From baseline (Day 1) to follow-up (Day 112)

  10. t½,SS: the terminal serum half-life of NNC0194-0499 at steady state

    Calculated based on serum concentrations of NNC0194-0499

    Time frame: From last dose (Day 78, pre-dose) until the follow-up (Day 112)

  11. Cmax,SS: the maximum concentration of NNC0194-0499 in serum at steady state

    Calculated based on serum concentrations of NNC0194-0499

    Time frame: From last dose (Day 78, pre-dose) until the follow-up (Day 112)

  12. tmax,SS: the time to maximum concentration of NNC0194-0499 in serum at steady state

    Calculated based on serum concentrations of NNC0194-0499

    Time frame: From last dose (Day 78, pre-dose) until the follow-up (Day 112)

  13. CL/F SS: the apparent total serum clearance of NNC0194-0499 at steady state

    Calculated based on serum concentrations of NNC0194-0499

    Time frame: From last dose (Day 78, pre-dose) until the follow-up (Day 112)

  14. Change in systolic blood pressure

    measured in mmHg

    Time frame: Baseline (Day 1), Follow-up (Day 112)

  15. Change in diastolic blood pressure

    measured in mmHg

    Time frame: Baseline (Day 1), Follow-up (Day 112)

08

Study locations

1 site
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78209, United States
09

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · www.novonordisk-trials.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Jun 2019, 14 months.

Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 14 months is above that.

Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2018
First posted
Mar 27, 2018
StartActual
Mar 13, 2018
Primary completionActual
Jun 4, 2019
CompletionActual
Jun 4, 2019
Last update
Jun 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03479892
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 27, 2018
Start date
Mar 13, 2018
Primary completion
Jun 4, 2019
Completion
Jun 4, 2019
Last update
Jun 26, 2019

Study contacts

Clinical Reporting Anchor and Disclosure (1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zalfermin

Start the discussion